The chemical biology of IL-12 production
Journal
RSC chemical biology
ISSN: 2633-0679
Titre abrégé: RSC Chem Biol
Pays: England
ID NLM: 101768727
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
received:
26
02
2020
accepted:
13
07
2020
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
31
8
2021
Statut:
epublish
Résumé
Interleukin-12 (IL-12) has emerged as an attractive cytokine for cancer therapy because it has direct anti-cancer effects and additionally plays a critical role in enhancing checkpoint inhibitors. Given these multiple modes of actions, identifying means to pharmacologically induce IL-12 production in the tumor microenvironment has become important. In this review, we highlight therapeutics that promote IL-12 induction in tumor-associated myeloid cells through the non-canonical NFkB pathway. We discuss existing clinical trials and briefly examine the additional pathway targets that warrant further exploration for drug discovery.
Identifiants
pubmed: 34458756
doi: 10.1039/d0cb00022a
pii: d0cb00022a
pmc: PMC8341911
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
166-176Subventions
Organisme : NCI NIH HHS
ID : R33 CA202064
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA079443
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA206997
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA240239
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206890
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA224348
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI084880
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218579
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI123349
Pays : United States
Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
RW is a consultant for Tarveda Pharmaceuticals, ModeRNA, Alivio Therapeutics, Lumicell, Accure Health, and Aikili Biosystems. These commercial relationships are unrelated to the current study. MJP is a consultant for AstraZeneca, Elstar Therapeutics, KSQ Therapeutics, Merck, and Siamab Therapeutics. These commercial relationships are unrelated to the current study. PDK: no relevant disclosures.
Références
J Clin Oncol. 2018 Sep 20;:JCO2017748392
pubmed: 30235087
Adv Urol. 2012;2012:181987
pubmed: 22778725
Nat Commun. 2017 Jan 16;8:14064
pubmed: 28091604
Sci Transl Med. 2015 Apr 15;7(283):283ra52
pubmed: 25877890
J Biol Chem. 2007 Feb 9;282(6):3688-94
pubmed: 17158868
Sci Transl Med. 2017 May 31;9(392):
pubmed: 28566423
J Biol Chem. 2003 Jun 27;278(26):23278-84
pubmed: 12709443
Immunity. 2014 Mar 20;40(3):342-54
pubmed: 24656046
Cancer Chemother Pharmacol. 2019 Oct;84(4):669-677
pubmed: 31187168
J Control Release. 2015 Oct 28;216:149-57
pubmed: 26282097
Nat Commun. 2017 Aug 24;8(1):344
pubmed: 28839138
Cancer Cell. 2010 Jul 13;18(1):9-10
pubmed: 20609349
J Immunol. 2007 Jun 1;178(11):6700-4
pubmed: 17513713
Curr Opin Immunol. 2013 Apr;25(2):230-7
pubmed: 23414607
J Control Release. 2019 Jul 28;306:165-176
pubmed: 31173789
Anticancer Agents Med Chem. 2008 Jun;8(5):533-9
pubmed: 18537535
Int Rev Immunol. 2012 Aug;31(4):279-88
pubmed: 22804572
Front Oncol. 2019 Nov 26;9:1256
pubmed: 31850192
Cell Chem Biol. 2020 Jan 16;27(1):94-104.e5
pubmed: 31902676
Cancer Immunol Res. 2020 Feb;8(2):246-254
pubmed: 31852717
Clin Cancer Res. 2015 Nov 15;21(22):5015-20
pubmed: 26567360
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11048-11053
pubmed: 30297432
Nanoscale. 2018 Nov 15;10(44):20851-20862
pubmed: 30403212
Cell. 2019 Jan 24;176(3):677
pubmed: 30682374
J Exp Med. 2018 May 7;215(5):1287-1299
pubmed: 29622565
Cell Chem Biol. 2017 Dec 21;24(12):1490-1500.e11
pubmed: 29056421
Biomaterials. 2017 Apr;123:118-126
pubmed: 28167390
J Innate Immun. 2018;10(5-6):398-406
pubmed: 30404092
Clin Cancer Res. 2015 Mar 15;21(6):1321-8
pubmed: 25589626
Cancer Immunol Immunother. 2019 Mar;68(3):395-405
pubmed: 30552459
Cell Mol Life Sci. 2001 Jan;58(1):4-43
pubmed: 11229815
Cell Res. 2011 Jan;21(1):71-85
pubmed: 21173796
Mol Cancer Ther. 2019 Jun;18(6):1025-1035
pubmed: 31015310
J Med Chem. 2012 May 10;55(9):4101-13
pubmed: 22413863
Nat Immunol. 2012 Nov;13(11):1101-9
pubmed: 23023393
Mini Rev Med Chem. 2016;16(4):309-22
pubmed: 26675675
Nat Biomed Eng. 2020 May;4(5):489-498
pubmed: 32203281
Immunity. 2020 Jan 14;52(1):36-54
pubmed: 31940272
Clin Cancer Res. 2013 Nov 15;19(22):6286-95
pubmed: 23983255
Cell. 2017 Jun 29;170(1):127-141.e15
pubmed: 28666115
J Control Release. 2019 Dec 10;315:114-125
pubmed: 31672626
Sci Immunol. 2018 Sep 7;3(27):
pubmed: 30194240
J Hematol Oncol. 2019 Mar 7;12(1):25
pubmed: 30845975
Cell Chem Biol. 2020 Jan 16;27(1):19-31.e6
pubmed: 31883964
Eur J Cancer. 2019 Aug;117:14-31
pubmed: 31229946
Bioconjug Chem. 2019 Mar 20;30(3):944-951
pubmed: 30830754
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
EMBO Rep. 2003 Jan;4(1):82-7
pubmed: 12524526
Theranostics. 2019 Nov 26;9(26):8426-8436
pubmed: 31879528
JAMA Oncol. 2020 Jan 01;6(1):100-107
pubmed: 31697308
Cell. 2007 Nov 16;131(4):682-93
pubmed: 18022363
J Clin Oncol. 2014 Oct 1;32(28):3103-10
pubmed: 25113756
Mol Cell. 2001 Feb;7(2):401-9
pubmed: 11239468
Biochem J. 2015 Feb 15;466(1):45-54
pubmed: 25423073
Nat Med. 2005 Feb;11(2):130-7
pubmed: 15665830
ACS Nano. 2020 Feb 25;14(2):1682-1693
pubmed: 31951368
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
Clin Cancer Res. 2015 Nov 15;21(22):5030-6
pubmed: 26567362
J Am Chem Soc. 2018 Dec 12;140(49):17019-17026
pubmed: 30444612
Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):227-41
pubmed: 26990581
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5552-7
pubmed: 27140638
J Biol Chem. 2008 Aug 22;283(34):23169-78
pubmed: 18550535
J Clin Oncol. 2007 Mar 1;25(7):876-83
pubmed: 17327609
Immunity. 2006 Sep;25(3):349-60
pubmed: 16979567
J Biol Chem. 2018 May 4;293(18):6776-6790
pubmed: 29545311
J Biol Chem. 2004 Jun 18;279(25):26243-50
pubmed: 15084608
Nat Immunol. 2008 Dec;9(12):1364-70
pubmed: 18997792
Trends Cancer. 2019 Sep;5(9):524-528
pubmed: 31474356
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
Cancer Immunol Immunother. 2014 May;63(5):419-35
pubmed: 24514955
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Eur J Immunol. 1996 Mar;26(3):659-68
pubmed: 8605935
Sci Transl Med. 2019 Jun 12;11(496):
pubmed: 31189721
Immunotherapy. 2018 Jul;10(9):787-796
pubmed: 29807457
Sci Rep. 2016 Jan 12;6:19049
pubmed: 26754564
Molecules. 2020 Feb 05;25(3):
pubmed: 32033280
Toxins (Basel). 2020 Apr 09;12(4):
pubmed: 32283684
J Cell Biol. 2006 Jun 5;173(5):659-64
pubmed: 16735576
Nat Chem Biol. 2005 Dec;1(7):377-82
pubmed: 16370373
J Med Chem. 2020 Mar 26;63(6):2731-2750
pubmed: 31682427
Nat Rev Drug Discov. 2013 Feb;12(2):147-68
pubmed: 23334208
Blood. 1994 Dec 15;84(12):4008-27
pubmed: 7994020
J Med Chem. 2013 Dec 27;56(24):9897-919
pubmed: 24320998
Nature. 2013 Feb 21;494(7437):371-4
pubmed: 23334419
Adv Exp Med Biol. 2019;1189:53-84
pubmed: 31758531
Carbohydr Polym. 2020 Mar 15;232:115764
pubmed: 31952581
Cell Chem Biol. 2020 Jan 16;27(1):66-73.e7
pubmed: 31859249
Theranostics. 2019 Oct 15;9(25):7714-7729
pubmed: 31695796
J Immunol. 2005 Nov 15;175(10):6997-7002
pubmed: 16272360
Nat Mater. 2014 Feb;13(2):125-38
pubmed: 24452356
ACS Nano. 2018 Dec 26;12(12):12015-12029
pubmed: 30508377
Biochem J. 2011 Feb 15;434(1):93-104
pubmed: 21138416
Breast Cancer Res Treat. 2013 Jan;137(2):359-71
pubmed: 23225169
Nat Commun. 2019 Apr 2;10(1):1486
pubmed: 30940805
Immunity. 2018 Sep 18;49(3):490-503.e4
pubmed: 30170810
F1000Res. 2015 Dec 17;4:
pubmed: 26918147
Nat Med. 2016 Dec;22(12):1411-1420
pubmed: 27841872
J Immunol. 1996 Feb 1;156(3):1207-12
pubmed: 8557999
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193
pubmed: 30655609
Methods Mol Biol. 2015;1280:269-82
pubmed: 25736754
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Nat Commun. 2018 Jan 12;9(1):179
pubmed: 29330524
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
ACS Nano. 2020 Jan 28;14(1):488-497
pubmed: 31765558
Sci Transl Med. 2020 Jan 15;12(526):
pubmed: 31941828
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32273347
Nat Rev Immunol. 2017 Sep;17(9):545-558
pubmed: 28580957
J Hematol Oncol. 2014 Jun 12;7:44
pubmed: 24919462
J Exp Med. 2006 Oct 30;203(11):2413-8
pubmed: 17015635
Drug Deliv Transl Res. 2020 Jun;10(3):661-677
pubmed: 32077052
Hum Vaccin Immunother. 2020;16(2):377-387
pubmed: 31403344
Front Pharmacol. 2017 May 31;8:304
pubmed: 28620298
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
Future Oncol. 2020 Jan;16(2):4359-4368
pubmed: 31823654
Nat Rev Drug Discov. 2019 Mar;18(3):175-196
pubmed: 30622344